# Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

> **NCT00785291** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 799 (actual)

## Conditions studied

- Estrogen Receptor Negative
- Estrogen Receptor Positive
- HER2/Neu Negative
- HER2/Neu Positive
- Progesterone Receptor Negative
- Progesterone Receptor Positive
- Recurrent Breast Carcinoma
- Stage IIIC Breast Cancer AJCC v6
- Stage IV Breast Cancer AJCC v6 and v7

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Ixabepilone
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Nab-paclitaxel
- **DRUG:** Paclitaxel
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT00785291
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-13
- **Primary completion:** 2013-12-31
- **Final completion:** 2017-06-15
- **Target enrollment:** 799 (ACTUAL)
- **Last updated:** 2022-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00785291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00785291, "Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00785291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*